Adverum Biotechnologies Inc (NASDAQ:ADVM)
| 1.19 Delayed Data As of Jun 02 |  +0.05 / +4.39%Today’s Change | 0.53 Today|||52-Week Range 1.82 | +105.35% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Quarter Trend | |||||
|---|---|---|---|---|---|---|
| Quarter 3 2018 | Quarter 4 2018 | Quarter 1 2019 | Quarter 2 2019 | |||
| Operating Activities | Net Income / Starting Line | -21.0M | -15.7M | -14.5M | -15.0M | |
| Depreciation | 262.0K | 389.0K | 965.0K | 959.0K | ||
| Total Other Cash Flow | 8.2M | 1.1M | 1.7M | 2.3M | ||
| Funds From Operations | -13.7M | -14.2M | -11.9M | -11.7M | ||
| Funds From/For Other Operating Expenses | 3.2M | -1.4M | 2.6M | -226.0K | ||
| Net Cash Flow - Operating Activities | -16.9M | -12.7M | -14.5M | -11.4M | ||
| Investing | Increase In Investments | -9.8M | -22.8M | -22.5M | -48.1M | |
| Decrease In Investments | 31.2M | 31.0M | 27.4M | 14.0M | ||
| Capital Expenditures | -270.0K | -157.0K | -2.2M | -2.5M | ||
| Net Cash Flow Investing | 21.1M | 8.0M | 2.7M | -36.6M | ||
| Financing | Short Term Borrowings | 0.00 | 0.00 | 1.2M | -158.0K | |
| Long Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Long Term Debt Reduction | -30.0K | -57.0K | 0.00 | 0.00 | ||
| Net Proceeds Stock Sale | 116.0K | 190.0K | 162.0K | 2.6M | ||
| Common Preferred Redeemed | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Common Dividends | -- | -- | -- | -- | -- | |
| Cash Dividends Paid - Total | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Sources - Financing | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Uses - Financing | 101.0K | 154.0K | 504.0K | 700.0K | ||
| Net Cash Flow - Financing | -15.0K | -21.0K | 872.0K | 1.7M | ||
| Exchange Rate | Effect of Exchange Rate on Cash | 0.00 | 0.00 | -- | -- | -- |
| Net Change In Cash | 4.2M | -4.7M | -10.8M | -46.3M | ||
